Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Charles Holz"'
Autor:
Pavel Strop, Russell Dushin, Janette Sutton, Guoyun Zhu, Davide Foletti, David L. Shelton, Shu-Hui Liu, Charles Holz, Arvind Rajpal, Hong Liang, Jaume Pons, Rachel M. DeVay, Gary Louis Bolton, Christine Bee, Kathy Delaria
Publikováno v:
Bioconjugate Chemistry. 28:1102-1114
Antibody drug conjugates (ADCs) provide an efficacious and relatively safe means by which chemotherapeutic agents can be specifically targeted to cancer cells. In addition to the selection of antibody targets, ADCs offer a modular design that allows
Autor:
Davide Foletti, Tina Mistry, Javier Chaparro-Riggers, Guoyun Zhu, Amy H. Yang, Xiaohui Liu, Pavel Strop, Charles Holz, Shu-Hui Liu, Laura Aschenbrenner, Thomas Van Blarcom, Winston Evering, Chenyu Lee, Adela Hasa-Moreno, Tao Sai, Eugenia Kraynov, Mathias Rickert, Sheng Ding, Kevin Lindquist, Jody Melton Witt, Leslie A. Obert
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports
Scientific Reports
Human CLDN18.2 is highly expressed in a significant proportion of gastric and pancreatic adenocarcinomas, while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the t
Autor:
Qing Zong, Bernard S. Buetow, Marco Costa, Charles Holz, David L. Shelton, Shu-Hui Liu, Thomas-Toan Tran, Allison Given Chunyk, Pavel Strop, Eileen R. Blasi, Jyothirmayee Kudaravalli, Kathy Delaria, Kevin Lindquist, Wei-Hsien Ho, Angela Stauffer, Jing-Tyan Ma, Magdalena Dorywalska, Arvind Rajpal
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-19 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-19 (2019)
Antibody-drug conjugates (ADCs) are promising therapies for haematological cancers. Historically, their therapeutic benefit is due to ADC targeting of lineage-restricted antigens. The C-X-C motif chemokine receptor 4 (CXCR4) is attractive for targete
Autor:
Sheng Ding, Tina Mistry, Tao Sai, Javier Chaparro-Riggers, Winston Evering, Guoyun Zhu, Pavel Strop, Jody Melton Witt, Amy H. Yang, Xiaohui Liu, Kevin Lindquist, Leslie A. Obert, Davide Foletti, Laura Aschenbrenner, Charles Holz, Adela Hasa-Moreno, Eugenia Kraynov, Mathias Rickert, Shu-Hui Liu, Chenyu Lee, Thomas Van Blarcom
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-1 (2019)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Autor:
Shawn E. Lupold, Charles Holz, Prakash Kulkarni, Sage Olson, Richard K. Baldwin, Robert Ivkov, Amarnath Mukherjee, Robert H. Getzenberg, Theodore L. DeWeese, Thomas K. Darlington
Publikováno v:
ChemMedChem. 9(7)
The prostate-specific membrane antigen (PSMA) is an established target for the delivery of cancer therapeutic and imaging agents due to its high expression on the surface of prostate cancer cells and within the neovasculature of other solid tumors. H
Understanding the mode of action for lipoxygenase (LOX) inhibitors is critical to determining their efficacy in the cell. The pseudoperoxidase assay is an important tool for establishing if a LOX inhibitor is reductive in nature, however, there have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2ddf6396816a1882b35c3636297371c
https://europepmc.org/articles/PMC3781013/
https://europepmc.org/articles/PMC3781013/